Vascular endothelial growth factor - Heparan sulfate - Vascular endothelial growth factor receptor 2 complex (VEGF-HS-VEGFR2)

The Vascular endothelial growth factor - Heparan sulfate - Vascular endothelial growth factor receptor 2 (VEGF-HS-VEGFR2) complex is a ternary signaling assembly essential for the regulation of angiogenesis and vascular permeability. In this interaction, heparan sulfate (HS) proteoglycans act as co-receptors that bind to the heparin-binding domain of VEGF-A, facilitating its presentation to the primary signaling receptor, VEGFR-2 (UniProt P15692, P35968). This HS-mediated stabilization is crucial for efficient receptor dimerization and the activation of downstream pathways, including the MAPK/ERK and PI3K/Akt cascades, which drive endothelial cell proliferation and migration (PubMed: 15569695). Pathologically, the overactivity of this complex is a hallmark of tumor-induced angiogenesis and neovascular disorders such as age-related macular degeneration and diabetic retinopathy (PubMed: 12359438). Therapeutic strategies targeting this interaction include monoclonal antibodies like bevacizumab and ranibizumab that sequester the VEGF ligand, and ramucirumab which directly blocks the VEGFR-2 extracellular domain (NIH: NCT00006042). Additionally, heparin mimetics such as muparfostat have been developed to disrupt the HS-dependent assembly of the complex. While these therapies are effective in slowing disease progression, they are associated with significant safety concerns, including systemic hypertension, proteinuria, and impaired wound healing, resulting from the inhibition of physiological VEGF signaling in healthy tissues.

Other names

VEGF-A/HSPG/VEGFR2 complexVEGF-HS-KDR interactionVEGF-heparin-VEGFR2 complexVEGF-A/VEGFR2/Heparan sulfate proteoglycan complex

Inhibition of VEGF ligand binding, blockade of VEGFR-2 receptor activation, and disruption of heparan sulfate-mediated complex stabilization.